newsroom.csl2d
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over ...
newsroom.csl8d
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure ...
newsroom.csl6d
OPTIONS XII IS COMING HOME
As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For ...
newsroom.csl2d
Global Newsroom
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL ...
newsroom.csl2d
Global Newsroom
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, ...